AtriCure to Present at the Seventh Annual JMP Securities Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jun 27, 2012-- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that it will present at the Seventh Annual JMP Securities Healthcare Conference at the Peninsula Hotel in New York on Friday, July 13, 2012. Management is scheduled to present at 10:30 a.m.
A live audio webcast and replay of the presentation will be available for 30 days following the presentation at www.atricure.com.
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage. For more information, please visit www.atricure.com.
CONTACT: AtriCure, Inc.
David J. Drachman, President and Chief Executive Officer, 513-755-5758 email@example.com KEYWORD: UNITED STATES NORTH AMERICA OHIO INDUSTRY KEYWORD: HEALTH CARDIOLOGY HOSPITALS MEDICAL DEVICES OTHER HEALTH GENERAL HEALTH SOURCE: AtriCure, Inc.
Copyright Business Wire 2012 PUB: 06/27/2012 04:15 PM/DISC: 06/27/2012 04:15 PM http://www.businesswire.com/news/home/20120627006358/